
Why Calgary wants your mosquitoes – dead or alive!
The City of Calgary is teaming up with the University of Calgary on a citizen science project examining mosquito ecology and the potential health implications of the invasive northern house mosquito, also known as culex pipiens.
The process is simple: just head to the Inglewood Bird Sanctuary or Ralph Klein Park to grab a mosquito kit – which comes with a collection tube and label – and use it to collect mosquitoes encountered in the park during your visit, whether alive or dead and squished.
You then fill out the label with the date, time and location, and drop off the sample in boxes within the parks.
'What we'll do, is then identify what the mosquito is, and that'll help us know where mosquitoes are throughout the city that are harassing people, and what species of mosquito they are,' said John Soghigian, an assistant professor of veterinary medicine at the University of Calgary.
'Of course, we also are still putting out traps all over the city and working with The City of Calgary to monitor mosquitoes, but sometimes it's hard to get at mosquitoes when they are actively seeking a host, so this helps us do that.'
Calgary collecting mosquitoes from citizens for science
Calgary is collecting mosquitoes from citizens for science in summer 2025.
Alex Coker, an integrated pest management technician with the City of Calgary, says citizens will start to see more mosquito activity now that the temperatures have climbed.
Calgary has 35 to 40 different mosquito species. All of them tend to lay their eggs near or in water.
'A lot of the mosquitoes we have here are floodwater mosquitoes, they use bodies of water that dry up multiple times through the year, so things like ditches are areas we tend to focus on when it comes to monitoring the larvae,' Coker said.
She cautioned that they also breed in rain barrels and bird baths, something for homeowners to keep in mind.
The City of Calgary uses a bacterial product to fight local mosquito populations.
It's dispensed by spraying it into bodies of water.
'Basically, the way it works is that the mosquitoes will ingest it … and it gets activated once they eat it, and basically it creates pores in the lining of their gut, and that's what kills them.'
If there is a lot of standing water throughout the city, officials can use an aerial program, which allows them to use a helicopter to apply the bacterial product to a large area over a short area of time.
If you've ever wondered why city officials can't just attempt to eradicate all the mosquitoes, it's because they actually are vital to the ecosystem.
Only female mosquitoes feed on blood; males rely solely on nectar as a food source, while females use both.
Because both males and female feed on nectar, they do act as pollinators and also serve as a food source for a lot of species including birds and dragonflies, and also aquatic organisms like fish.
Coker says mosquito numbers in Calgary typically peak in July.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
26 minutes ago
- Globe and Mail
FDA Extends Review Period of REGN's Submission for Eylea HD
Regeneron Pharmaceuticals, Inc. ( REGN ) announced that the FDA has extended the target action dates for Eylea HD (aflibercept) injection 8 mg regulatory submissions. Eylea HD is the higher dose of Eylea. The regulatory body has now extended the target action dates to the fourth quarter of 2025 for two regulatory submissions for Eylea HD (aflibercept) Injection 8 mg. The submission includes a Chemistry, Manufacturing and Controls Prior-Approval Supplement for the Eylea HD prefilled syringe and a supplemental biologics license application seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week (monthly) dosing across approved indications. Despite the extension announcement, REGN shares were up 3.4%. This information was previously communicated by the company during its second-quarter earnings release. This is probably because Eylea HD remains available in the United States through vial administration. Regeneron's shares have lost 17% year to date against the industry 's gain of 3.8%. More on REGN's Eylea HD The FDA extended the review periods after determining that the information submitted following a recent inspection of a third-party manufacturer constituted a major amendment to each application. The anticipated delay resulted from observations during an FDA general site inspection of Catalent Indiana LLC, which Novo Nordisk A/S ( NVO ) acquired in December 2024. Novo Nordisk submitted a comprehensive response in early August 2025 to address the observations noted by the FDA. Eylea HD is approved with dosing intervals every 8 to 16 weeks for patients with wet age-related macular degeneration and diabetic macular edema, and every 8 to 12 weeks for patients with diabetic retinopathy, following three initial monthly doses. Eylea HD (known as Eylea 8 mg in the European Union and Japan) is being jointly developed by Regeneron and Bayer AG ( BAYRY ). While Regeneron holds exclusive rights to Eylea and Eylea HD in the United States, BAYRY holds the exclusive marketing rights outside the country. REGN and BAYRY equally share the profits from sales of Eylea and Eylea HD. REGN Banks on Eylea HD and Dupixent for Growth Regeneron's performance in the second quarter was encouraging. The company has finally managed to post revenue growth despite declining sales of lead drug Eylea. Eylea sales continue to decline due to competition from Vabysmo. To counter the decline in Eylea sales, Regeneron has developed a higher dose of the drug. Eylea HD sales in the United States surged 29% in the second quarter due to higher sales volumes driven by increased demand. REGN's top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi ( SNY ) records global net product sales of Dupixent. SNY and REGN are working to expand the drug's label further. The FDA had earlier approved Dupixent for chronic obstructive pulmonary disease (COPD). The approved indication is an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. Consistent label expansions of Dupixent continue to fuel its sales and help REGN earn higher profits. REGN is looking to strengthen its oncology portfolio to diversify its revenue stream. The recent progress with its oncology pipeline has been encouraging. The approval of Lynozyfic is a boost for its oncology portfolio. Zacks Rank Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report

National Post
26 minutes ago
- National Post
Altasciences Chosen by Steel Therapeutics to Support the Launch of Pivotal Toxicology Study for Fizurex™
Article content LAVAL, Québec — Altasciences is pleased to have been chosen by Steel Therapeutics, Inc. ('Steel'), to initiate a pivotal toxicology study for Fizurex™, a novel topical therapy for the treatment of anal fissures. Article content The GLP-compliant study is currently being conducted at Altasciences' preclinical facility in Columbia, MO. It marks a key milestone in Steel's regulatory development, as the company prepares for an Investigational New Drug (IND) application in early 2026. Article content 'We're proud to be supporting Steel Therapeutics at this key stage of their development journey,' Article content said Steve Mason, Co-COO at Altasciences. Article content 'Our teams are aligned in their commitment to accelerate the delivery of patient-centered therapies. The initiation of this study is another example of how early collaboration and scientific rigor can bring important treatments closer to market.' Article content Fizurex™, a patent-pending compounded wipe, has seen widespread use in clinical practice and is now progressing through the formal regulatory pathway to reach broader patient populations under FDA oversight. Steel engaged Altasciences due to their deep expertise in preclinical safety evaluation and proven ability to execute with speed and precision. Article content 'Working with Altasciences allows us to maintain the highest standards of quality as we move Fizurex™ into its next phase of development,' Article content said Matt Stahl, CEO and Founder of Steel Therapeutics. Article content 'This study represents a major step forward for our company and for the patients who stand to benefit from more consistent, scalable access to this treatment.' Article content Altasciences' integrated, collaborative approach to drug development enables companies like Steel to move efficiently from discovery through to clinical trials, all under one organizational umbrella. Article content 'We look forward to continuing our partnership with Steel Therapeutics as they advance their portfolio of innovative, patient-focused therapies,' Article content added Mason. Article content preclinical Article content and Article content clinical pharmacology Article content studies, including Article content formulation, manufacturing, and analytical services Article content . For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include Article content preclinical safety testing Article content , Article content clinical pharmacology and proof of concept Article content , Article content bioanalysis Article content , program management, Article content research support Article content , medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Article content . Article content About Steel Therapeutics Article content Steel Therapeutics' Article content mission is to improve the lives of patients by scaling access to compounded drugs that have a proven track record of safety and effectiveness. With a team of pharmacist-founders who have built and operated retail compounding programs, Steel is well-positioned to identify both high-impact drug candidates and innovative delivery systems. Article content Steel has selected a novel treatment for anal fissures as its product entry point. The company's Fizurex™ wipe utilizes a combination therapy that is commonly compounded by pharmacists and incorporates it into a single-use wipe. By bringing rigorous safety and efficacy testing, Current Good Manufacturing Practices (CGMP), and a patient-friendly format to this drug combination, Steel believes it can dramatically improve outcomes for patients. Article content Article content Article content Contacts Article content Article content Article content


CBC
28 minutes ago
- CBC
Quebec announces investments in preventative health care measures
Quebec says it wants to get ahead of chronic illnesses and invest more in screenings and pilot projects to detect at-risk individuals. It's part of the provincial government's preventative health care strategy, released Thursday, which Minister of Health Christian Dubé hopes will help ease pressure off the network. "We really have to act at the source. The sustainability of our health care network depends on it," said Dubé, during a news conference this morning. Over the next 10 years, Dubé says he wants to see a 10 per cent reduction in the impact of chronic illnesses in Quebec and a 10 per cent reduction in the gap in premature mortality linked to socioeconomic inequalities. For its first year, the plan includes a $5 million investment into screenings for Type 2 diabetes and HPV, among other illnesses. Dubé says he wants to re-purpose some of the infrastructure set up for COVID-19 tests and vaccinations and turn them into "prevention centres." The provincial strategy also targets tobacco dependence with a $4 million investment and seeks to promote physical activity among the more sedentary sectors of the population with a $5 million investment. Other measures include smaller investments into research and public participation. "We have major challenges, we know it, but notably due to the aging of the population," said Dubé. "It's not because it's not okay to age, but we have to be able to live with the impacts and to work on that."